Karl Pfleger is the founder of agingbiotech.info and an investor in several rejuvenation startups.

Topics we discuss are well captured by the timestamps below.

Watch on YouTube or X. Listen on Apple Podcasts, Spotify, or any other podcast platform. Follow me on X for updates on future episodes.

Timestamps

0:00 - Why lifespan is the wrong metric for aging progress

7:28 - Is the hallmarks of aging expanding a problem?

11:36 - Structures vs. processes: the key distinction in aging targets

16:14 - Why Karl favors divide-and-conquer rejuvenation over slowing aging

22:07 - Whole-body replacement and organ/cell-level rejuvenation

26:56 - Is partial epigenetic reprogramming the kill-shot for aging?

35:24 - CMLase and reversing crosslink damage

40:57 - Can AI just solve aging automatically?

46:57 - Funding misallocation and the case for more aging biotech companies/VC

57:28 - Objections to eliminating aging — and why none hold up

1:01:27 - Karl critiques Bryan Johnson’s “Don’t Die”

Arjun Khemani